Overview

Epigenetic Reprogramming in Relapse/Refractory AML

Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a pilot study using decitabine and vorinostat before and during chemotherapy with fludarabine, cytarabine and G-CSF (FLAG).
Phase:
Phase 1
Details
Lead Sponsor:
Therapeutic Advances in Childhood Leukemia Consortium
Treatments:
Cytarabine
Decitabine
Fludarabine
Fludarabine phosphate
Lenograstim
Vorinostat